Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Perl

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Cancers|November 14, 2023
A Phase I Trial of Sirolimus with "7&3" Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid LeukemiaNeil Palmisiano, Grace Jeschke, Lindsay Wilde, et al.
Leukemia & Lymphoma|June 7, 2006
A predictive model for the detection of tumor lysis syndrome during AML induction therapyAnthony R Mato, Brett E Riccio, Li Qin, et al.
Cancer Research|June 20, 2017
A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220Panpan Hou, Chao Wu, Yuchen Wang, et al.
Small (Weinheim an Der Bergstrasse, Germany)|May 23, 2022
Biocoating-A Critical Step Governing the Oral Delivery of Polymeric NanoparticlesAharon Azagury, Cameron Baptista, Kosta Milovanovic, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2021
Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
Journal of Clinical Pharmacology|June 30, 2020
Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid LeukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
Blood|November 5, 2005
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulationDavid L Porter, Bruce L Levine, Nancy Bunin, et al.
Blood Advances|March 19, 2024
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemiaMark Levis, Alexander Perl, Gary Schiller, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Cancer Biology & Therapy|January 6, 2007
Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexaroteneDonald E Tsai, Selina M Luger, Allison Kemner, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Cancers|November 14, 2023
A Phase I Trial of Sirolimus with "7&3" Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid LeukemiaNeil Palmisiano, Grace Jeschke, Lindsay Wilde, et al.
Leukemia & Lymphoma|June 7, 2006
A predictive model for the detection of tumor lysis syndrome during AML induction therapyAnthony R Mato, Brett E Riccio, Li Qin, et al.
Cancer Research|June 20, 2017
A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220Panpan Hou, Chao Wu, Yuchen Wang, et al.
Small (Weinheim an Der Bergstrasse, Germany)|May 23, 2022
Biocoating-A Critical Step Governing the Oral Delivery of Polymeric NanoparticlesAharon Azagury, Cameron Baptista, Kosta Milovanovic, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2021
Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
Journal of Clinical Pharmacology|June 30, 2020
Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid LeukemiaDongwoo Kang, Elizabeth Ludwig, David Jaworowicz, et al.
Blood|November 5, 2005
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulationDavid L Porter, Bruce L Levine, Nancy Bunin, et al.
Blood Advances|March 19, 2024
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemiaMark Levis, Alexander Perl, Gary Schiller, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 5, 2015
Outpatient Autologous Stem Cell Transplantation for Patients With MyelomaThomas M Paul, Stephen V Liu, Elise A Chong, et al.
Cancer Biology & Therapy|January 6, 2007
Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexaroteneDonald E Tsai, Selina M Luger, Allison Kemner, et al.
Pageof 3